A LinkedIn post from Insilico Medicine highlights the company’s presence at major industry forums, noting CEO Alex Zhavoronkov’s upcoming appearance at the CNBC Converge Live event in Singapore. According to the post, his session, titled “AI in Practice: Trials, Treatment and Outcomes,” will focus on moving beyond AI hype to discuss real‑world applications in healthcare.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post indicates that the session will explore how AI may improve outcomes at scale, the evolving ownership of patient relationships, and where clinical and commercial value might ultimately accrue in the healthcare ecosystem. For investors, this type of high‑visibility thought‑leadership platform could support Insilico Medicine’s positioning as a credible player in AI‑driven drug discovery and healthcare technology.
As shared in the post, the company is simultaneously engaging with the oncology research community at AACR 2026 in San Diego, where it is directing attendees to its booth to discuss KRAS data and recent updates to its Pharma.AI platform. This dual presence at a scientific conference and a business media event suggests an effort to reach both technical and commercial stakeholders, which could help attract partners, accelerate adoption of its platforms, and potentially support future revenue opportunities.